Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Secondary
1.6.1.1 Paid sources
1.6.1.2 Public sources
1.6.2 Primary
Chapter 2 Executive Summary
2.1 Veterinary Auto-immune Therapeutics Market 3600 Synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Therapy type trends
2.1.4 Disease trends
2.1.5 Animal type trends
2.1.6 Distribution channel trends
Chapter 3 Veterinary Auto-immune Therapeutics Market Industry Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing threat of transfer of zoonotic diseases among humans
3.2.1.2 Rising incidence of auto-immune diseases in livestock animals
3.2.1.3 Increasing awareness and diagnosis of autoimmune diseases
3.2.1.4 Increasing companion animal ownership
3.2.1.5 Increasing expenditure on animal healthcare
3.2.1.6 Increasing in animal health medicalization rate
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of veterinary auto-immune therapies
3.2.2.2 Increase risk of infection due to auto-immune drugs
3.3 Growth potential analysis
3.3.1 By therapy type
3.3.2 By disease
3.3.3 By animal type
3.3.4 By distribution channel
3.3.5 By Region
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Veterinary Auto-immune Therapeutics Market Size and Forecast, By Therapy Type (USD Million)
5.1 Key trends, by therapy type
5.2 Corticosteriods
5.3 Azathioprine
5.4 Cyclosporine
5.5 Mycophenolate
5.6 Leflunomide
5.7 Cyclophosphamide
5.8 Levothyroxine
5.9 Folic acid
6.10 Hydroxychloroquine
6.11 Chloroquine
Chapter 6 Veterinary Auto-immune Therapeutics Market Size and Forecast, By Disease (USD Million)
6.1 Key trends, by disease
6.2 Hypothyroidism
6.3 Pemphigus disease
6.4 Canine lupus
6.5 Auto-immune haemolytic anaemia
6.6 Bullous pemphigoid
6.7 Discoid lupus erythematosus (DLE)
6.8 Immune-related arthritis
6.9 Other diseases
Chapter 7 Veterinary Auto-immune Therapeutics Market Size and Forecast, By Animal Type (USD Million)
7.1 Key trends, by animal type
7.2 Companion animals
7.2.1 Dogs
7.2.2 Cats
7.2.3 Horses
7.2.4 Other companion animals
7.3 Livestock animals
7.3.1 Cattle
7.3.2 Swine
7.3.3 Poultry
7.3.4 Sheep
7.3.5 Other livestock animals
7.4 Other animals
Chapter 8 Veterinary Auto-immune Therapeutics Market Size and Forecast, By Distribution Channel (USD Million)
10.1 Key trends, by distribution channel
10.2 Veterinary hospitals
10.3 Veterinary clinics
Chapter 9 Veterinary Auto-immune Therapeutics Market Size and Forecast, By Country (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
12.1 Aratana Therapeutics, Inc.
12.2 Pfizer Inc.
12.3 Vet-Stem, Inc.
12.4 Ambrx, Inc.
12.5 Taconic Biosciences, Inc.
12.6 JBS United
12.7 Virbac
12.8 Eli Lily and Company
12.9 Jaguar Animal Health Inc.
